无症状颈动脉狭窄患者的最佳药物治疗:神话还是现实?
本研究回顾性评估了120例无症状颈动脉狭窄≥60%患者对最佳药物治疗的实施与依从性,并比较药物治疗组与颈动脉内膜切除术组的脑血管/冠状动脉事件风险。药物治疗组60例中2年随访时3例(5%)发生卒中,其中1例死亡;手术组围手术期卒中发生率为3%,均未致残或致死。作者认为多数患者未能严格依从药物治疗,指南的「一刀切」策略可能不适用于所有患者。
要点
- 药物治疗组60例中2年随访时3例(5%)发生卒中,其中1例死亡。
- 颈动脉内膜切除术组围手术期卒中发生率为3%,均未致残或致死。
- 仅33例达到血压控制、正常体重、他汀联合/不联合依折麦布及抗血小板治疗,其中仅5例同时达到低密度脂蛋白<70 mg/dL、血红蛋白A1c<7%且不吸烟。
核心结论
- 尽管近期一些研究报告无症状颈动脉狭窄≥50%患者在接受最佳药物治疗时同侧卒中风险仅为每年0.34%,但在日常实践中多数患者未能严格依从药物治疗。
- 作者认为「一刀切」的指南策略可能不适用于所有患者,特定无症状颈动脉狭窄患者的管理可能需要个体化。
研究设计与样本
- 回顾性评估在本院经颈动脉超声识别的无症状颈动脉狭窄≥60%患者。
- 选择最佳药物治疗的患者若随访期不足2年、失访、临床信息缺失或接受颈动脉支架置入则被排除。
- 最终回顾性评估最后120例连续患者,其中60例接受颈动脉内膜切除术,60例接受最佳药物治疗。
- 数据收集由医院报告系统支持,数据录入专门创建的数据库,统计分析使用SPSS-25软件。
主要发现
- 大多数患者有高血压(n=107;89%)、血脂异常(n=101;84%),40%有糖尿病,33%诊断冠心病,32%超重或肥胖,17%为当前吸烟者。
- 血压控制、正常体重、他汀联合/不联合依折麦布及抗血小板治疗仅在33例中达到,仅5例 additionally 达到低密度脂蛋白<70 mg/dL、血红蛋白A1c<7%且不吸烟。
- 药物治疗组60例中,2年随访时3例(5%)发生卒中,其中1例死亡。
- 颈动脉内膜切除术组围手术期卒中记录于3%的患者,均未致残或致死。
- 21例患者超过6个月出现同侧事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 1.4 million strokes/year causing about 1.1 million deaths annually occur in Europe and 10%-15% of those strokes are result of thromboembolism from a previously significant asymptomatic carotid stenosis (ACS). Medical treatment has improved considerably in the last 15 years; however, its success depends on patient compliance. The aim of our study was to evaluate, in patients with ACS, the implementation and patient adherence to best medical treatment (BMT). Additionally, we sought to determine the "real-world" incidence of cerebrovascular/coronary events in a cohort of nonoperated ACS patients and weighing this risk against surgical complications in patients with ACS undergoing surgical treatment at our Department. METHODS: Patients with ACS ≥ 60% identified by a carotid ultrasound performed at our Department were retrospectively evaluated. Patients selected to BMT were excluded if the follow-up period was inferior to 2 years, as well as patients lost in follow-up, with missing clinical information and submitted to carotid stenting. Patients' data collection was supported by hospital reporting system and data were introduced into a database created for the purpose. Statistical analysis was performed using SPSS-25 software. RESULTS: After exclusion criteria were applied, the last 120 consecutive patients (60 with ACS submitted do carotid endarterectomy and 60 with ACS under BMT) were retrospectively evaluated. Twenty one patients had ipsilateral events for more than 6 months. Most patients had hypertension (n = 107; 89%), dyslipidemia (n = 101; 84%), 40% had diabetes, 33% diagnosed coronary disease, 32% were overweight or obese, and 17% were current smokers. Blood pressure control, normal weight, statin with/without ezetimibe association, and antiaggregant therapy were only achieved in 33 patients and only 5 had additionally low-density lipoprotein levels < 70 mg/dL, hemoglobin A1c < 7%, and were nonsmokers. Of the 60 patients assigned to medical treatment, 3 (5%) had a stroke at 2 years of follow-up, which was fatal in 1 patient. Among patients submitted to carotid endarterectomy, perioperative stroke was documented in 3% of the patients, none of them disabling or fatal. CONCLUSIONS: Although some recent studies report a risk of ipsilateral stroke of only 0.34% per year in patients with ACS ≥ 50% under BMT therapy in our everyday practice strict compliance to medical treatment fails in most patients. In consequence, we think that a "one-size-fits-all" guideline policy may not be appropriate for all patients and the management of specific ACS patients may need to be individualized.
引用
- Constâncio Oliveira V, Oliveira P, Silva E, et al. Best Medical Treatment in Patients with Asymptomatic Carotid Stenosis: Myth or Reality? Ann Vasc Surg. 2023. PMID: 37088360. doi:10.1016/j.avsg.2023.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。